000 | 02007 a2200541 4500 | ||
---|---|---|---|
005 | 20250518072243.0 | ||
264 | 0 | _c20201001 | |
008 | 202010s 0 0 eng d | ||
022 | _a2326-6074 | ||
024 | 7 |
_a10.1158/2326-6066.CIR-19-0315 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aGalliverti, Gabriele | |
245 | 0 | 0 |
_aMyeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV _h[electronic resource] |
260 |
_bCancer immunology research _c01 2020 |
||
300 |
_a131-145 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xpharmacology |
650 | 0 | 4 |
_aCD8-Positive T-Lymphocytes _ximmunology |
650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 | _aDrug Synergism |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmunosuppression Therapy |
650 | 0 | 4 |
_aImmunotherapy _xmethods |
650 | 0 | 4 | _aMice |
650 | 0 | 4 |
_aMyeloid Cells _xdrug effects |
650 | 0 | 4 |
_aNanoparticles _xadministration & dosage |
650 | 0 | 4 |
_aPapillomaviridae _ximmunology |
650 | 0 | 4 |
_aPapillomavirus E7 Proteins _ximmunology |
650 | 0 | 4 |
_aPapillomavirus Infections _xdrug therapy |
650 | 0 | 4 |
_aPapillomavirus Vaccines _xadministration & dosage |
650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
650 | 0 | 4 | _aTumor Microenvironment |
650 | 0 | 4 |
_aUterine Cervical Neoplasms _xdrug therapy |
700 | 1 | _aWullschleger, Stephan | |
700 | 1 | _aTichet, Mélanie | |
700 | 1 | _aMurugan, Dhaarini | |
700 | 1 | _aZangger, Nadine | |
700 | 1 | _aHorton, Wesley | |
700 | 1 | _aKorman, Alan J | |
700 | 1 | _aCoussens, Lisa M | |
700 | 1 | _aSwartz, Melody A | |
700 | 1 | _aHanahan, Douglas | |
773 | 0 |
_tCancer immunology research _gvol. 8 _gno. 1 _gp. 131-145 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1158/2326-6066.CIR-19-0315 _zAvailable from publisher's website |
999 |
_c30356704 _d30356704 |